Immunology companies study and manipulate the immune system to develop therapies, diagnostics and research tools. The field plays a central role in areas such as cancer, infectious disease, autoimmune disorders and vaccine development.
This category includes companies working on:
Browse 182 UK immunology companies below.
TSG-6 protein therapeutics for inflammatory and degenerative disease
Link Biologics is a preclinical-stage biotechnology company developing protein therapeutics based on TSG-6, an endogenous human protein with anti-inflammatory and tissue-protective properties. Spun out from the University of Manchester in 2021, the company is advancing its lead asset, Link_TSG6, across programmes in…
Ovine polyclonal therapeutics developer and antivenom manufacturer
MicroPharm is a specialty pharmaceutical company developing and manufacturing ovine polyclonal antibody therapeutics for the treatment of acute toxic and infectious conditions. The company's MHRA-licensed facilities in West Wales produce a portfolio of clinical-grade antivenoms, including products acquired from Sanofi…
RNA therapeutics targeting cellular senescence and age-related disease
Senisca is a preclinical-stage biotechnology company developing oligonucleotide and small molecule therapeutics that reverse cellular senescence by restoring RNA splicing factor activity. Its platform targets the molecular mechanisms of cellular ageing and has broad applicability across multiple age-related diseases.…
Biomedical discovery institute researching the molecular basis of disease
The MRC Laboratory of Medical Sciences is a biomedical discovery research institute studying the molecular and physiological basis of health and disease. Scientists and clinicians collaborate across three core research areas, including epigenetics and stem cell development, genes and metabolism, and quantitative…
Antibody therapeutics for inflammatory and autoimmune disease
MabGalaxy develops antibody therapeutics for inflammatory and autoimmune diseases, with scientific operations linked to Cambridge's Babraham Research Campus. Its discovery approach combines immune-system biology with artificial intelligence to support antibody design and selection. The company aims to shorten the…
In vitro respiratory and inhalation toxicology testing services
ImmuONE is a contract research company specialising in in vitro inhalation toxicology and respiratory safety assessment. The company develops and applies human alveolar macrophage and epithelial cell culture models to evaluate the safety and efficacy of inhaled compounds, providing an alternative to animal testing.…
Global biopharma with UK R&D hub in Hertfordshire
Roche Products is the UK pharmaceutical arm of F. Hoffmann-La Roche, headquartered at Welwyn Garden City in Hertfordshire. The site employs over 1,900 people and serves as a primary hub for early-stage drug discovery, clinical development, computational sciences, and commercial operations. The UK operation contributes…
AI platform engineering molecular glue drugs for undruggable targets
Ternary Therapeutics is a preclinical-stage biotechnology company developing an AI-driven platform for the rational design of molecular glue therapeutics. Molecular glues are small molecules that induce proximity between two proteins, enabling targeted degradation or modulation of disease-driving targets that lack…
Specialist oncology CRO for early and late phase clinical trials
Theradex (Europe) Limited is the European arm of Theradex Oncology, a US-founded CRO with over 40 years specialising in oncology clinical development. The company provides full-service clinical trial management for pharma and biotech sponsors across early and late phase studies, with expertise in oncology,…
In vivo lentiviral CAR/TCR cell therapy platform for ovarian cancer
Akimbo Bio is an early-stage biotechnology company developing next-generation in vivo lentiviral vector technology for cell therapy. Its lead platform carries a dual CAR/TCR payload designed for direct in vivo delivery, with an initial focus on ovarian cancer. The technology uses intelligent receptor crosstalk, in…
IgE and IgA antibody therapeutics for cancer treatment
Epsilogen is a clinical-stage biotech pioneering the development of non-IgG immunoglobulin antibody therapeutics for cancer. The company's platform spans IgE, IgA, and IgG isotypes, enabling selection of the most appropriate antibody format for a given tumour type. Its lead candidate MOv18 IgE, the first IgE antibody…
Steroid-free dermatology formulations and investigational GL-1 platform
Gran Lab is a Queen's University Belfast spin-out developing biochemical formulations for inflammatory and reactive skin conditions. Its investigational GL-1 topical platform is being developed as a non-steroidal approach to psoriasis and related dermatoses, with laboratory studies ongoing and clinical trials in…
Ex vivo haematopoietic stem cell gene therapies for rare genetic diseases
Orchard Therapeutics is a gene therapy company developing ex vivo haematopoietic stem cell therapies for rare genetic diseases, primarily severe neurometabolic and immunological disorders in children. Its platform modifies a patient's own stem cells with a functional copy of the defective gene before reinfusion. Lead…
Bispecific antibody platform for cancer immunotherapies
F-star Therapeutics is a clinical-stage biotechnology company developing tetravalent bispecific antibodies for cancer and other serious diseases. Its proprietary platform creates antibodies with four binding sites that simultaneously target two different antigens, enabling focused immune activation in the tumour…
Therapeutic cancer vaccines based on recombinant overlapping peptide technology
Oxford Vacmedix is a clinical-stage biopharma company developing therapeutic cancer vaccines using its proprietary Recombinant Overlapping Peptide (ROP) platform. ROPs stimulate broad T cell and antibody immunity without HLA restriction, enabling a universal immunotherapy approach. The lead programme, OVM-200, targets…
Systemic viral immunotherapy for solid tumours
Stratosvir develops engineered viral immunotherapies for advanced solid tumours and their metastases. Its platform aims to overcome the limitations of injecting therapeutic viruses directly into tumours by enabling systemic, intravenous delivery. Within tumour tissue, the viruses are designed to replicate selectively…
CAR T cell therapies for blood cancer and autoimmune disease
Autolus Therapeutics is a London-based commercial-stage biopharma developing next-generation programmed T cell therapies. Its lead product AUCATZYL (obecabtagene autoleucel) received FDA approval in November 2024 and MHRA conditional marketing authorisation in 2025 for relapsed or refractory B-cell acute lymphoblastic…
World leading centre researching viral diseases of farm animals
The Pirbright Institute researches viral diseases of farm animals and viruses that spread from animals to humans. The Institute works to predict, detect and respond to livestock diseases, developing vaccines and diagnostic tests that support global food security and public health. Its high containment laboratories…
AI-driven skin microbiome platform for skincare and drug discovery
Biotix is a biotechnology company applying artificial intelligence and microbiome science to discover and develop novel approaches for skin health. Its AI platform analyses proprietary microbiome and clinical datasets to identify beneficial skin microbes and their metabolites, supporting both a commercial skincare…
Global biopharma focused on neurology and rare disease therapeutics
Biogen is a global biopharma company and one of the world's first biotechnology firms. The UK and Ireland headquarters in Maidenhead employs approximately 250 people across clinical operations, regulatory affairs, drug safety, and medical affairs. The company develops and commercialises therapies for neurological,…